INDIA – The India AMR Innovation Hub (IAIH) has welcomed Venus Remedies Limited as a key member with an aim of fast-tracking national efforts against antimicrobial resistance (AMR) for a larger global health impact.
Conceptualised and driven by the Centre for Cellular and Molecular Platforms (C-CAMP), the main objective of the IAIH is to introduce appropriate interventions for nurturing an AMR innovation ecosystem in India.
The India AMR Innovation Hub is a unique Convergent Think Tank on AMR Interventions comprised of Indian and global stakeholders, including government, industry and philanthropic organizations, hospitals along with academic and research institutions.
IAIH’s existing members include WHO, Bill and Melinda Gates Foundation, FIND, PATH, DNDi, Narayana Health, Zydus Cadila, Johnson & Johnson, Elanco, Godrej Agrovet, ICMR, DBT, ICAR, and ChanRe Rheumatology and Immunology Centre and Research to mention a few.
Venus Remedies, an India-based research pharmaceutical company, joining the global multi-stakeholder platform will facilitate opportunities for future collaborations on antibiotic resistance and infection prevention and control.
The pharma company will work closely with IAIH’s members to develop suitable public health policies, build capacities, nurture state-of-the-art R&D and undertake AMR stewardship activities to curb the evolution and spread of drug resistant pathogens.
It is an ideal opportunity for Venus Remedies to build on its track record of responsible manufacturing and access to antibiotics, encouraging appropriate antibiotic use, antibiotic stewardship activities in the clinical domain and developing new breakthrough therapeutics.
The company set up a non-profit organisation called Preserving Life of Existing Antibiotics (PLEA) to facilitate a comprehensive understanding of the incidence, causes and patterns of AMR in the country.
In addition, the India AMR Innovation Hub and Venus Remedies have a shared holistic AMR viewpoint of leveraging collective efforts and fostering international cooperation to tackle the rising threat of antimicrobial resistance.
The partnership will also help to drive new sustainable solutions to AMR, shape relevant AMR policies, as well as bridge the gaps in antibiotic research and manufacturing with focus on access and rational use.
Venus Remedies will play a crucial role in steering IAIH’s mission to nurture an AMR innovation ecosystem in India, and ultimately becoming an anchor for effecting a systemic change in the Indian AMR research and innovation landscape.
Meanwhile, the Saudi Food and Drug Authority (SFDA) recently awarded Venus Remedies Limited with a good manufacturing practices (GMP) certification for its unit in Baddi, Himachal Pradesh, India.
Venus Remedies has also received marketing authorisations for its generic cancer drugs from Uzbekistan and Palestine that will benefit thousands of patients as well as the broader healthcare community.